A Phase Ib, Dose-Finding Study of Oral Panobinostat (LBH589) in Combination with Idarubicin and Cytarabine Induction and High-Dose Cytarabine-Based Consolidation Therapy in Adult Patients Less and or Equal to 65 Years Old with Acute Myeloid Leukemia (AML).

Trial Profile

A Phase Ib, Dose-Finding Study of Oral Panobinostat (LBH589) in Combination with Idarubicin and Cytarabine Induction and High-Dose Cytarabine-Based Consolidation Therapy in Adult Patients Less and or Equal to 65 Years Old with Acute Myeloid Leukemia (AML).

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Panobinostat (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Sep 2013 Planned end date changed from 1 May 2015 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 12 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top